Peer Review History
| Original SubmissionAugust 30, 2019 |
|---|
|
PONE-D-19-24478 Influenza-associated excess mortality in the Philippines, 2006-2015 PLOS ONE Dear Mr. Cheng, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Two reviewers agree that your manuscript needs a major revision, so please address all of their comments on methodological and statistical modelling issues before resubmitting. We would appreciate receiving your revised manuscript by Nov 30 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Joël Mossong Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for providing the following Funding Statement:"Funding: Sanofi Pasteur." We note that one or more of the authors are employed by a commercial company: name of commercial company. a) Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission for Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement. b). Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests 3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide.
Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No Reviewer #3: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors estimated influenza-associated mortality in the Philippines, which added one more component to understand the global burden of influenza. In general, this paper was well written, and I have some comments below. 1. What contributes to the sharp peak in death in 2008 for children aged 5-9 years? 2. The authors could consider to add a dummy variable in the regression model to adjust for the impact of Typhoon Haiyan, like what has been done to adjust for SARS outbreak. 3. Why would the effects of temperature and relative humidity be opposite in different age groups? 4. The mathematical formula is incorrect. In the negative binomial model, there should be a log link between dependent and independent variables. 5. In table 1, why there is a substantial decrease of samples tested in 2014 and 2015. Is there any change of influenza surveillance system in Philippines? 6. The axes of the figures could be revised to make the figures more readable. Reviewer #2: This manuscript estimates Influenza-associated excess mortality in the Philippines during the period 2006 through 2015 using negative binomial regression models. As the authors indicate, mortality burden of influenza in the Philippines has not been quantified before thus findings from this manuscript will help to inform public health policies and strategies for the control of influenza. Here are some comments that the authors could consider to help the readers to better understand their study and the findings that they present. 1. In line 78: The authors state, “No adjustment was made for under-registration of deaths”. Before that, the authors indicate that deaths “must be registered within 48 hours”. Isn’t this a contradiction? It would be of help to the readers if the authors could state why no adjustments were made for under-registration. Is it that no data are available to quantify deaths that are not registered, or perhaps that there is so much variation by site/hospital or region in the country to allow for meaningful adjustments? 2. The authors indicate that GISRS data were collected through ILI and SARI cases at sentinel sites. Can they include the case definitions used for ILI and SARI or provide appropriate references for the readers? 3. I note that the authors used a weekly time-series to model the overall and age-specific EMRs associated with influenza. Did the authors consider using time-lagged independent variables (particularly for meteorological variables and influenza activity)? This is not stated in the text and one would expect a time-lagged effect of these variables on mortality. 4. Also, is there a particular reason why the meteorological variables (rainfall, temperature, and humidity) were included in the model to estimate EMRS? Has there been data to suggest that these are important for the Philippines? Did inclusion of these variables result in better fitting models, across the age groups assessed? 5. In lines 118-119, the authors state the “Other missing data were not replaced in the principal analyses”. This is somehow ambiguous. Could the authors state what these data are? 6. Reading through the methods, I assume that the data from the 2009 pandemic period were included in the analyses, is this correct? If so, I would suggest that the authors rerun the analyses with the pandemic data excluded. This is particularly important if they are seeking to estimate the mean annual EMRs associated with influenza. A quick look at the data suggests an additional few hundred deaths (~300 deaths) annually if the data from the pandemic period are included. 7. Related to that, I suggest that the authors only model the estimates using the imputed deaths for week 45 in 2013 (when the typhoon Haiyan occurred). Regardless of the fact that they conducted sensitivity analyses, it is clear that the spike in deaths during that week was out of the ordinary and thus it would only make sense if it were excluded. 8. The authors mention that the 95% CIs were estimated using bootstrapping methods with 1,500 iterations. However, I note that the CIs are very narrow, particularly for data among young children <5 years. Could the authors look again at this, and perhaps comment about it in the discussion? 9. In lines 208-209, the authors state “…. and influenza was the cause of approximately one in every 100 deaths”. This is not explicit in the results section but I suppose that this is based on dividing the total mean annual all-cause deaths by the mean annual influenza-associated deaths. Could the authors try to make this more explicit in the text? This further highlights why you should not include the 2009 pandemic data in your EMRs models. Reviewer #3: The authors intend to quantify mortality associated to influenza in the Philippines, which is very important for public health and prevention. Hence, this is a very important paper. Some general comments: The authors use three metrological measures, rain, temperature and humidity, which each also have seasonal variation. Therefore, the inclusion of the yearly and half-yearly sines must have been included to adjust for residual seasonality not covered by these metrological variables. Argue why a negative binomial regression (compensate for over-dispersion – what about under-dispersion?) Additive or multiplicative model? – link function Selection of elements to be included in the model is based on having positive A and B coefficients – argue why - and secondly the lowest AIC. However, in the S2 Table I miss this information. Figure 2 show huge peaks in number of deaths associated to influenza in week 45 2013 (The typhoon Haiyan), This I don’t understand. - Was there a huge peak in positive influenza samples that week? – I do not believe so, probably none or very few samples were sampled in that week. - As there are no peaks in the model (red line) in figure 1, and the number of deaths associated to influenza was calculated as the prediction from the full model minus the prediction by the same model, but with A and B set to zero. There should not be calculated peaks. This indicate that the calculation of influenza-associated number of deaths is wrong! Would be nice to show both the full models and the models with A and/or B as zero in graph 1. Suggest including graphs showing the A and B positive percentages over calendar time used in the model and as supplementary the metrological parameters. The authors intend to compare all-cause influenza-associated mortality with cause-specific influenza-associated mortality. The most commonly used cause-specific mortality is respiratory (ICD10 …) e.g. references 1 and 2. The authors only look at J10 and J11 (influenza the main cause of deaths). This is of cause interesting, but it would have been of more interest, if they (also) had looked at respiratory cause of deaths, and made serious comparisons, for example if there is a general relation e.g. has it been suggested that influenza-associated mortality estimated using all-cause is the double of respiratory. Alternatively, the authors could leave out cause-specific influenza-associated mortality, and write another article comparing all-cause and cause-specific. Suggest to include a typhoon Haiyan parameter in the model: 1 in week 45 2013, else 0. The Philippines consist of many islands with varying population. The metrological stations are properly distributed more-or-less evenly over the whole area, why average metrological measures should be population weighted. Likewise for the influenza data. Is this possible? – if not, this should be discussed as a limitation. Minor comments: Page 3, line 64: I believe ‘mortality has not been accurately quantified’ attribute too much faith in the model. Suggest to leave out ‘accurately’. Page 4, line 66-67: ‘… and compare …’. Suggest ‘… and compare all-cause estimates with influence cause-specific estimates’. Page 4, line 78: Is it correct that all deaths in the Philippines are registered with cause of deaths within 48 hours? – Faster than in any other country, I know of. Page 4, line 81-86: What do you mean by and what is the difference between ILI sentinel sites and SARI (Severe acute respiratory infections) sites? – how many of each? Page 5, line 93. I cannot find ‘average weekly temperature’ in reference 13, only average daily min and max temperatures. Page 5, line 105: Ok to use a polynomial spline, but why 6? Page 6, line 118: ‘Other missing data …’ - how many? Page 13, line 212-215. I believe it is highly surprising that this studies all-cause influenza-associated mortality estimates are consistent with the respiratory-cause-specific estimates from Iuliano et al. study Page 13, line 223: I would not use the word ‘accurately’, but something like our model fitted data well Page 13, line 223-4: Sometimes ‘official deaths registry statistics’ stand for cause-specific and here for all-cause. Suggest using all-cause and cause-specific. Page 13, line 224: It is not correct that your model predicted the typhoon Haiyan peak! – see figure 1 Page 14-15, line 252-255: You might have used, what is often called the Goldstein index: ILI-rate * positive-percentage, where the ILI rate reflect the population dynamics and the positive-percentage limit the ILI-rate to influenza i.e. exclude other circulating respiratory pathogens. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Xiling Wang Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 1 |
|
Influenza-associated excess mortality in the Philippines, 2006-2015 PONE-D-19-24478R1 Dear Dr. Cheng, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Joël Mossong Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: (No Response) Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: No further comments, the manuscript have been correctly and thoroughly revised and I believe it's ready for publication. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No |
| Formally Accepted |
|
PONE-D-19-24478R1 Influenza-associated excess mortality in the Philippines, 2006-2015 Dear Dr. Cheng: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Joël Mossong Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .